ATE177644T1 - Verwendung von decorin oder biglycan zur herstellung eines medikaments für die behandlung von diabetes-bedingter zustände - Google Patents

Verwendung von decorin oder biglycan zur herstellung eines medikaments für die behandlung von diabetes-bedingter zustände

Info

Publication number
ATE177644T1
ATE177644T1 AT93900930T AT93900930T ATE177644T1 AT E177644 T1 ATE177644 T1 AT E177644T1 AT 93900930 T AT93900930 T AT 93900930T AT 93900930 T AT93900930 T AT 93900930T AT E177644 T1 ATE177644 T1 AT E177644T1
Authority
AT
Austria
Prior art keywords
fibrosis
biglycan
decorin
medication
treatment
Prior art date
Application number
AT93900930T
Other languages
English (en)
Inventor
Erkki I Ruoslahti
Wayne A Border
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Application granted granted Critical
Publication of ATE177644T1 publication Critical patent/ATE177644T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93900930T 1991-12-04 1992-12-04 Verwendung von decorin oder biglycan zur herstellung eines medikaments für die behandlung von diabetes-bedingter zustände ATE177644T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80328591A 1991-12-04 1991-12-04

Publications (1)

Publication Number Publication Date
ATE177644T1 true ATE177644T1 (de) 1999-04-15

Family

ID=25186123

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93900930T ATE177644T1 (de) 1991-12-04 1992-12-04 Verwendung von decorin oder biglycan zur herstellung eines medikaments für die behandlung von diabetes-bedingter zustände

Country Status (10)

Country Link
EP (1) EP0616536B1 (de)
JP (2) JP3854307B2 (de)
AT (1) ATE177644T1 (de)
AU (2) AU670770B2 (de)
CA (1) CA2124591A1 (de)
DE (1) DE69228700T2 (de)
DK (1) DK0616536T3 (de)
FI (1) FI942622A (de)
NO (1) NO942072L (de)
WO (1) WO1993010808A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847007A (en) * 1993-05-13 1998-12-08 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US20030130324A1 (en) * 1993-11-19 2003-07-10 Johnston W. Mcavoy Method for preventing or controlling cataract
WO1995026203A1 (en) * 1994-03-29 1995-10-05 The Victoria University Of Manchester Wound healing
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
WO1999034823A2 (en) * 1998-01-09 1999-07-15 University Of Utah METHODS FOR PREVENTING AND TREATING FIBROTIC DISEASES RESULTING FROM ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX INDUCED BY TGFβ USING RENIN INHIBITORS
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
EP2130532A1 (de) 1999-01-05 2009-12-09 University of Utah Research Foundation Verfahren zur Behandlung von mit der Akkumulation von überschüssiger extrazellulärer Matrix assoziierten Zuständen
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
US6864236B1 (en) * 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
GB0102673D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
ATE420654T1 (de) 2001-08-15 2009-01-15 Univ Brown Res Found Behandlung von muskeldystrophien und verwandter erkrankungen
CA2473829A1 (en) * 2002-01-22 2003-07-31 Genzyme Corporation Use of tgf-.beta. antagonists to treat or to prevent chronic transplant rejection
WO2004075917A1 (ja) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. 器官または組織の線維化抑制剤
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP2230252A1 (de) 2006-03-13 2010-09-22 The Johns Hopkins University Erhöhung der endothelialen Thromboresistenz
EP1983345A1 (de) * 2007-04-17 2008-10-22 Roche Diagnostics GmbH Mittel und Verfahren zur Bewertung des Risikos eines Herzeingriffs bei Patienten, die an einer auf GDF-15 basierenden stabilen Erkrankung der Herzkorona leiden
EP3117709B1 (de) 2010-03-12 2018-08-01 Genzyme Corporation Kombinationstherapie zur behandlung von brustkrebs
JP6339367B2 (ja) 2010-05-17 2018-06-06 ブラウン ユニバーシティ バイグリカン変異体および関連する治療薬および使用方法
WO2012092299A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
KR20130131414A (ko) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 ｉＰＳ 세포와 그 제조법
MX351600B (es) 2011-06-03 2017-10-20 Xoma Technology Ltd Anticuerpo especificos para tgf-beta.
EP3553169B1 (de) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
EP3804760A1 (de) 2013-10-31 2021-04-14 Kyoto Prefectural Public University Corporation Therapeutikum für erkrankungen im zusammenhang mit endoplasmatischem retikulumszelltod im hornhautendothel
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
WO2017223268A1 (en) * 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
JP7109039B2 (ja) 2016-07-07 2022-07-29 国立大学法人千葉大学 抗線維症剤およびリン酸化Ｓｍａｄ核内移行阻害剤
KR102141125B1 (ko) * 2018-01-22 2020-08-05 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
WO2019143219A1 (ko) * 2018-01-22 2019-07-25 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물
FR3090320B1 (fr) * 2018-12-19 2023-03-03 Karim Bouzakri Utilisation de la decorine dans le traitement du diabete
KR20200120878A (ko) * 2019-04-11 2020-10-22 고려대학교 산학협력단 비글리칸을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780780B2 (ja) * 1989-09-29 1995-08-30 ラ ホヤ キャンサー リサーチ ファウンデーション 細胞外マトリックスの蓄積防止のためのトランスフォーミング増殖因子βの阻害
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors

Also Published As

Publication number Publication date
NO942072L (no) 1994-08-03
EP0616536A1 (de) 1994-09-28
NO942072D0 (no) 1994-06-03
JP3854307B2 (ja) 2006-12-06
WO1993010808A1 (en) 1993-06-10
AU670770B2 (en) 1996-08-01
DK0616536T3 (da) 1999-10-11
DE69228700T2 (de) 1999-09-09
FI942622A0 (fi) 1994-06-03
FI942622A (fi) 1994-07-27
JPH07504650A (ja) 1995-05-25
CA2124591A1 (en) 1993-06-10
AU7051896A (en) 1997-01-16
JP2004043507A (ja) 2004-02-12
AU3242993A (en) 1993-06-28
DE69228700D1 (de) 1999-04-22
EP0616536B1 (de) 1999-03-17

Similar Documents

Publication Publication Date Title
ATE177644T1 (de) Verwendung von decorin oder biglycan zur herstellung eines medikaments für die behandlung von diabetes-bedingter zustände
JP5528380B2 (ja) 修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
JPS6429308A (en) Treatment of hyperhydrosis, psoriasis and wrinkle
ATE141799T1 (de) Die kombination des wachshormons und des insulin- ähnlichen wachstumsfaktors-i stimuliert das wachstum
ATE372782T1 (de) Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin- abhängigen diabetes
DE60107253D1 (de) Verwendung von edelmetallen zur herstellung eines arzneitmittels zur behandlung von hyperproliferativen hautstörungen und krankheiten
Bertsch et al. Effect of mechanical stimulation on cell proliferation in mouse epidermis and on growth regulation by endogenous factors (chalones)
Okabe et al. Wound treatment using growth factors
DE69228749T2 (de) Neuartige polypeptide und ihre verwendung
CN110179823A (zh) 一种基于金属多酚配位的活细胞递送系统及其制备方法
DE4125400A1 (de) Verwendung von kollagen zur behandlung von degenerativen gelenkprozessen
DE194851T1 (de) Therapie der menschlichen tumore.
Paunio et al. The effect of chlorhexidine gluconate on the formation of experimental granulation tissue.
Manley et al. Distribution of mucopolysaccharides in the human vascular tree
DE3852870T2 (de) Saurer Fibroblast-Wachstumsfaktor-Mutant.
JPH02117698A (ja) 血管内皮細胞成長因子
Katiyar et al. Pathology of inflammatory‐reparative response in punched wounds of the chicken skin
EP0320785A3 (de) Peptide mit beeinflussender Wirkung auf die Hypophyse von Säugern
DE3855331T2 (de) Regulierung der zellenproliferation und differenzierung mittels peptiden
KR20170041914A (ko) 제2형 진성 당뇨병 및 이의 합병증의 치료를 위한 펩티드
DE2336560C2 (de) Arzneimittel, enthaltend l-(2-Hydroxy-2-indanyl)-propylamin
WO1988006037A1 (en) Application of dextran sulphate in the production of a drug for the treatment and prophylaxis of vasoconstriction and vascular occlusion
DE2149470C3 (de) Prednisonderivat, Verfahren zu seiner Herstellung und dieses enthaltendes Mittel
Dazrulhafizi et al. Effectiveness of Collagen Extracted From the Skin of Nile Tilapia Fish (Oreochromis niloticus) to Accelerate Wound Healing in vivo: A Narrative Review
McGee et al. Methodical variation of subcutaneous insulin injection sites.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties